

---

STATUTORY INSTRUMENTS

---

**2021 No. 169**

**The National Health Service (Charges and  
Pharmaceutical and Local Pharmaceutical Services)  
(Coronavirus) (Amendment) Regulations 2021**

**Amendment of regulation 2 of the PLPS Regulations**

2. In regulation 2(1) of the PLPS Regulations<sup>(1)</sup> (interpretation), at the appropriate place insert—
- ““prescription item” means an item available on prescription, whether or not it is supplied in pursuance of a prescription or another basis for supply (for example a serious shortage protocol or a patient group direction);” and
- ““PTPGD” means a pandemic treatment patient group direction, which is a patient group direction—
- (a) relating to the supply of a prescription only medicine to be used for the prevention of or as a treatment for a disease that is, or in anticipation of it being imminently, pandemic; and
  - (b) which is in accordance with regulation 233 of the Human Medicines Regulations 2012<sup>(2)</sup> (exemption for supply etc under a PGD by a person conducting a retail pharmacy business);”.

---

(1) Regulation 2 has been amended by [S.I. 2015/137](#), [570](#), [1862](#) and [1879](#), [2016/696](#) and [1077](#), [2018/1114](#), [2019/593](#), [990](#) and [1094](#), and [2020/351](#) and [1126](#).

(2) [S.I. 2012/1916](#); regulation 233 has been amended by [S.I. 2013/235](#), [2015/1053](#) and [2020/1594](#).